Systemic Sclerosis

You have full text access to this OnlineOpen article

The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France

  1. Eric Hachulla1,†,*,
  2. Pascal de Groote2,
  3. Virginie Gressin3,‡,
  4. Jean Sibilia4,§,
  5. Elisabeth Diot5,
  6. Patrick Carpentier6,¶,
  7. Luc Mouthon7,‖,
  8. Pierre-Yves Hatron1,††,
  9. Patrick Jego8,
  10. Yannick Allanore7,‡‡,
  11. Kiet Phong Tiev9,
  12. Christian Agard10,
  13. Anne Cosnes11,
  14. Daniela Cirstea12,
  15. Joël Constans13,
  16. Dominique Farge14,
  17. Jean-François Viallard15,
  18. Jean-Robert Harle16,
  19. Frédéric Patat17,
  20. Bernard Imbert6,
  21. André Kahan7,§§,
  22. Jean Cabane9,
  23. Pierre Clerson18,
  24. Loïc Guillevin7,¶¶,
  25. Marc Humbert19

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24525

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1831–1839, June 2009

Additional Information

How to Cite

Hachulla, E., de Groote, P., Gressin, V., Sibilia, J., Diot, E., Carpentier, P., Mouthon, L., Hatron, P.-Y., Jego, P., Allanore, Y., Tiev, K. P., Agard, C., Cosnes, A., Cirstea, D., Constans, J., Farge, D., Viallard, J.-F., Harle, J.-R., Patat, F., Imbert, B., Kahan, A., Cabane, J., Clerson, P., Guillevin, L. and Humbert, M. (2009), The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis & Rheumatism, 60: 1831–1839. doi: 10.1002/art.24525

Author Information

  1. 1

    Hôpital Claude Huriez, Lille, France

  2. 2

    Centre Hospitalier Régional Universitaire, Lille, France

  3. 3

    Actelion Pharmaceuticals France, Paris, France

  4. 4

    Hôpital de Hautepierre, Strasbourg, France

  5. 5

    Hôpital Bretonneau, Tours, France

  6. 6

    Hôpital Nord, Grenoble, France

  7. 7

    Hôpital Cochin, Paris, France

  8. 8

    Hôpital Sud, Rennes, France

  9. 9

    Hôpital St. Antoine, Paris, France

  10. 10

    Hôtel Dieu, Nantes, France

  11. 11

    Hôpital Henri Mondor, Créteil, France

  12. 12

    Hôpital Central, Nancy, France

  13. 13

    Hôpital St. André, Bordeaux, France

  14. 14

    Hôpital St. Louis, Paris, France

  15. 15

    Hôpital du Haut Lévesque, Pessac, France

  16. 16

    Hôpital de la Conception, Marseilles, France

  17. 17

    Université François Rabelais, Tours, France

  18. 18

    Orgamétrie, Roubaix, France

  19. 19

    Université Paris-Sud 11, and Hôpital Antoine Béclère, Assistance Publique Hôpitaux de Paris, Clamart, France

  1. †

    Dr. Hachulla has received consulting fees, speaking fees, and/or honoraria from Actelion, Pfizer, and GlaxoSmithKline (less than $10,000 each).

  2. ‡

    Dr. Gressin owns stock or stock options in Actelion.

  3. §

    Dr. Sibilia has received speaking fees from Actelion (less than $10,000).

  4. Dr. Carpentier has received honoraria as a member of the Scientific Committee on Scleroderma for Actelion France (less than $10,000).

  5. ‖

    Dr. Mouthon has received consulting fees, speaking fees, and/or honoraria from Actelion and LFB (less than $10,000 each).

  6. ††

    Dr. Hatron has received honoraria from Pierre Fabre Laboratories and Pfizer (less than $10,000 each).

  7. ‡‡

    Dr. Allanore has received consulting fees, speaking fees, and/or honoraria from Actelion and Encysive (less than $10,000 each).

  8. §§

    Dr. Kahan has received consulting fees, speaking fees, and/or honoraria from Actelion (less than $10,000).

  9. ¶¶

    Dr. Guillevin has received speaking fees and honoraria from Actelion (less than $10,000).

*Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille 2, 59037 Lille Cedex, France

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 17 FEB 2009
  4. Manuscript Received: 5 AUG 2008

Funded by

  • Actelion Pharmaceuticals France

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (96K)

REFERENCES

  • 1
    Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 940–4.
  • 2
    Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, and the ItinérAIR-Sclérodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford) 2009; 48: 304–8.
  • 3
    Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792–800.
    Direct Link:
  • 4
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 5
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.
  • 6
    Gibbs JS, Higenbottam TW. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86 Suppl 1: i1–13.
  • 7
    The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little, Brown; 1994. p. 253–6.
  • 8
    Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 Suppl S: 40S–7S.
  • 9
    Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 Suppl S: 5S–12S.
  • 10
    Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35: 458–65.
  • 11
    Kessler R, Faller M, Weitzenblum E, Chaouat A, Ayrut A, Ducolone A, et al. Natural history of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219–24.
  • 12
    Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892–6.
  • 13
    Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088–93.
  • 14
    Vonk MC, Broers B, Heijdra YF, Ton E, Snijders R, van Dijk AP, et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2008. E-pub ahead of print.
  • 15
    MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453–9.
  • 16
    Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966: 238–46.
    Direct Link:
  • 17
    Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 269–74.
  • 18
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81: 139–53.
  • 19
    Simeon CP, Armadans L, Fonollosa R, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42: 71–5.
  • 20
    De Groote P, Gressin V, Hachulla E, Carpentier P, Guillevin L, Kahan A, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31–6.
  • 21
    Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58: 1803–9.
    Direct Link:
  • 22
    Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765–70.
    Direct Link:
  • 23
    Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro–brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284–91.
    Direct Link:
  • 24
    Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516–22.
    Direct Link:
  • 25
    Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007; 66: 754–63.
View Full Article (HTML) Get PDF (96K)